BioSpace News Archive

Blue Earth Diagnostics announced additional results from its Phase 3 LIGHTHOUSE trial that evaluated the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer.

Pharming Group N.V. announces that the European Medicines Agency’s Committee for Human Medicinal Products has decided to shift its assessment of the Marketing Authorisation Application for leniolisib to a standard review timetable.

Eurofins Viracor LLC announces the launch of a ground-breaking test that can assess the expansion and persistence of Chimeric Antigen Receptor T-Cell therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.

IRLAB Therapeutics AB announced that the company will hold a presentation in conjunction with the publication of the year-end report for the period January-December 2022.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the fourth quarter ended December 31, 2022, and provided a business update.

AQILION AB announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 protein.

Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration for the company’s Millipede 088 Access Catheter.

Rockwell Medical, Inc. announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2022 on Thursday, March 30, 2023.

Talaris Therapeutics, Inc., announced that it has completed a review of its business and program prospects.

NexImmune, Inc. announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.